GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guangzhou Kingmed Diagnostics Group Co 603882.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

27.90

-2.55%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥6.03bn

FY2016FY2025

Net income

−CN¥173.2m

FY2016FY2025

Free cash flow

CN¥778.6m

FY2016FY2025

Shareholders' equity

CN¥6.73bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥6.03bnCN¥7.19bnCN¥8.54bnCN¥15.48bnCN¥11.94bnCN¥8.24bnCN¥5.27bnCN¥4.53bnCN¥3.79bnCN¥3.22bn
Gross profitCN¥2.10bnCN¥2.38bnCN¥3.12bnCN¥6.67bnCN¥5.65bnCN¥3.85bnCN¥2.08bnCN¥1.76bnCN¥1.55bnCN¥1.36bn
Research and developmentCN¥341.3mCN¥400.5mCN¥467.1mCN¥632.6mCN¥517.9mCN¥397.2mCN¥324.0mCN¥290.8mCN¥256.0mCN¥238.2m
Operating incomeCN¥242.3m−CN¥273.2mCN¥759.8mCN¥3.35bnCN¥2.78bnCN¥1.82bnCN¥437.8mCN¥304.0mCN¥247.7mCN¥217.8m
Net income−CN¥173.2m−CN¥381.2mCN¥643.4mCN¥2.75bnCN¥2.22bnCN¥1.51bnCN¥402.3mCN¥233.3mCN¥188.5mCN¥170.0m
Diluted earnings per share-0.37-0.821.375.904.833.300.870.510.480.45

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥9.60bnCN¥10.39bnCN¥11.77bnCN¥13.89bnCN¥10.75bnCN¥6.64bnCN¥4.40bnCN¥3.96bnCN¥3.32bnCN¥2.67bn
Cash and short-term investments—CN¥2.43bnCN¥2.46bnCN¥2.93bnCN¥2.65bnCN¥1.64bnCN¥954.9mCN¥842.0mCN¥649.4mCN¥529.8m
Total liabilitiesCN¥2.75bnCN¥2.92bnCN¥3.22bnCN¥5.02bnCN¥4.23bnCN¥2.76bnCN¥2.07bnCN¥2.00bnCN¥1.58bnCN¥1.53bn
DebtCN¥575.7mCN¥634.3mCN¥448.9mCN¥568.3mCN¥622.1mCN¥461.5mCN¥614.7mCN¥745.8mCN¥576.8mCN¥706.4m
Shareholders' equityCN¥6.73bnCN¥7.33bnCN¥8.36bnCN¥8.63bnCN¥6.30bnCN¥3.79bnCN¥2.27bnCN¥1.91bnCN¥1.70bnCN¥1.10bn
Shares outstanding463m463m469m467m460m458m460m456m397m378m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥1.20bnCN¥906.3mCN¥1.23bnCN¥1.95bnCN¥2.09bnCN¥1.52bnCN¥661.4mCN¥529.6mCN¥283.5mCN¥292.1m
Capital spending−CN¥423.5m−CN¥446.4m−CN¥714.7m−CN¥840.5m−CN¥952.4m−CN¥550.7m−CN¥274.9m−CN¥346.3m−CN¥379.9m−CN¥429.7m
Free cash flowCN¥778.6mCN¥460.0mCN¥516.1mCN¥1.11bnCN¥1.14bnCN¥972.5mCN¥386.5mCN¥183.4m−CN¥96.3m−CN¥137.6m
Dividends paid−CN¥413.9m−CN¥419.6m−CN¥839.3m−CN¥596.2m−CN¥152.2m−CN¥62.3m−CN¥49.5m−CN¥40.5m−CN¥35.2m−CN¥32.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.53bnCN¥1.35bnCN¥1.49bnCN¥1.54bnCN¥1.53bnCN¥1.47bnCN¥1.57bnCN¥1.74bn
Gross profitCN¥587.5mCN¥471.4mCN¥514.8mCN¥563.3mCN¥529.4mCN¥487.6mCN¥407.8mCN¥626.3m
Operating incomeCN¥172.4mCN¥63.5m−CN¥32.5mCN¥38.1m−CN¥69.9m−CN¥36.2m−CN¥383.5mCN¥8.1m
Net incomeCN¥147.4mCN¥42.8m−CN¥93.6mCN¥5.2m−CN¥57.0m−CN¥27.8m−CN¥475.1mCN¥4.2m
Diluted earnings per share0.320.09-0.200.01-0.12-0.06-1.030.01
Cash from operations———CN¥327.0mCN¥295.0mCN¥55.0m—CN¥277.0m
Capital spending−CN¥94.0m−CN¥108.0m−CN¥131.0m−CN¥117.0m−CN¥67.0m−CN¥106.0m−CN¥99.0m−CN¥139.0m
Free cash flow———CN¥210.0mCN¥228.0m−CN¥51.0m—CN¥138.0m
Total assetsCN¥9.14bnCN¥9.20bnCN¥9.60bnCN¥9.71bnCN¥9.78bnCN¥9.85bnCN¥10.39bnCN¥10.98bn
Cash and short-term investments———CN¥2.44bnCN¥2.18bnCN¥1.99bnCN¥2.43bnCN¥1.94bn
DebtCN¥575.0mCN¥589.2mCN¥575.7mCN¥209.0mCN¥607.8mCN¥638.4mCN¥515.9mCN¥439.8m
Shareholders' equityCN¥6.31bnCN¥6.35bnCN¥6.73bnCN¥6.83bnCN¥6.82bnCN¥6.89bnCN¥7.33bnCN¥7.83bn

Financial ratios

Data as of 2 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin34.7%33.1%36.5%43.1%47.3%46.7%
Operating margin4.0%-3.8%8.9%21.6%23.2%22.0%
Net margin-2.9%-5.3%7.5%17.8%18.6%18.3%
Return on equity-2.6%-5.2%7.7%31.9%35.2%39.9%
Return on assets-1.8%-3.7%5.5%19.8%20.6%22.7%
Free cash flow yield12.1%10.0%14.3%20.5%22.7%15.6%
Revenue growth-16.1%-15.8%-44.8%29.6%44.9%56.4%
Earnings growth-54.6%-159.3%-76.6%24.1%47.0%275.2%
Current ratio3.24x3.28x3.07x2.33x2.13x2.06x
Debt to equity0.09x0.07x0.03x0.02x0.04x0.11x
Equity ratio70.1%70.5%71.1%62.1%58.6%57.0%
Interest coverage16.50x-13.07x32.02x124.11x92.06x58.40x
R&D as a share of sales5.7%5.6%5.5%4.1%4.3%4.8%
Buybacks as a share of market value0.0%1.2%-0.3%-1.5%-0.5%0.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-27.0%-6.1%9.7%
Operating income-58.3%-33.2%3.5%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin33.9%38.3%41.4%41.3%
Operating margin-0.2%10.9%15.1%13.1%
Net margin-4.2%7.6%11.4%10.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-75.8-33.545.613.323.138.958.643.566.6
Price to sales2.21.83.42.44.37.14.52.23.3

Dividends and splits

Per share, in the currency the company pays

Paid for 8 years. Last went ex-dividend on 5 Feb 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.880.880.881.781.280.3290.1360.108

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.